Navigation Links
New animal study shows promise for development of Parkinson's disease drug
Date:6/9/2011

Amsterdam, NL, 9 June 2011 Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

Parkinson's disease is the second most common neurodegenerative disorder, affecting 1𔃀% of the population over the age of 65. It is characterized by loss of brain cells (neurons) from the mid-brain which use the neurotransmitter dopamine to help control voluntary movements. Investigators from NeuroNova AB, Stockholm, Sweden, the Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, The Parkinson's Institute, Sunnyvale, CA, USA, and Motac Neuroscience Ltd, Manchester, UK, found that behavioral, tissue and biochemical changes in experimental models of Parkinson's disease in rodents could be counteracted by infusion of PDGF-BB. This could offer an alternative strategy to restore function in PD.

"In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase," commented Anders Haegerstrand, MD, PhD, Chief Scientific Officer, NeuroNova AB, Stockholm, Sweden."It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of neural progenitor cells in the subventricular zone. The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease."


'/>"/>

Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. Mammary gland development of blueberry-fed lab animals studied
2. Animal results may pave way to treating rare mitochondrial diseases in children
3. Study finds pigs susceptible to virulent ebolavirus can transmit the virus to other animals
4. Animal studies reveal new route to treating heart disease
5. Animal-assisted therapy decreases patient anxiety in pre-MRI setting, study suggests
6. Multiple Pregnancies May Up Risk of Obesity, Diabetes: Animal Study
7. New drug shrinks cancer in animals, U-M study shows
8. Animal Hoarding Often Tied to Mental Illness
9. Animal Study May Explain Low Birth Weight-Obesity Link
10. Speaker series highlights the role of animals in human culture
11. Researchers discover way to halt lung inflammation in animal models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for ... Reduction Program (HRRP), the return of a patient to the hospital within 30 days ... many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017  Noble ... coverage on ESSA Pharma Inc. (Nasdaq: EPIX ... Biotechnology Research, Kumar Raja , PhD. ... treatments for castration resistant prostate cancer (CRPC). Its lead ... selectively blocks the amino-terminal domain of the androgen receptor, ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. ... specialty pharmaceutical company, today announced that executive management will ... to be held February 22-23, 2017. Adrian Adams ... the Company at 1:35 p.m. local time on Wednesday, ... audio archive for the event may be accessed from ...
Breaking Medicine Technology: